8-K: Karyopharm Reports Q3 2025 Growth, SENTRY Trial Progress

Karyopharm Therapeutics announced increased Q3 2025 revenue and reduced operating loss, alongside key clinical trial advancements for its cancer therapies.

Summary

• Total revenue for Q3 2025 was $44.0 million, an increase from $38.8 million in Q3 2024.
• U.S. XPOVIO net product revenue reached $32.0 million in Q3 2025, up 8.5% from $29.5 million in Q3 2024.
• Royalty revenue increased to $1.5 million in Q3 2025 from $0.9 million in Q3 2024, driven by international partners.
• The Phase 3 SENTRY trial in myelofibrosis completed enrollment with 353 patients in early September 2025, with top-line data expected in March 2026.
• Preliminary blinded aggregate safety data from the first 61 SENTRY patients may suggest improvements in adverse events compared to previous data.
• Full-year 2025 total revenue guidance was reaffirmed at $140 million to $155 million.
• Full-year 2025 U.S. XPOVIO net product revenue guidance was reaffirmed at $110 million to $120 million.
• The range for R&D and SG&A expenses for full-year 2025 was lowered to $235 million to $245 million.
• Net loss for Q3 2025 was $33.1 million, or $3.82 per share, compared to a net loss of $32.1 million, or $3.85 per share, in Q3 2024.
• Cash, cash equivalents, restricted cash, and investments totaled $46.2 million as of September 30, 2025, with a proforma balance of approximately $78 million after recent financing.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive, driven by revenue growth, improved operating loss, successful completion of a pivotal Phase 3 trial enrollment, and reaffirmed/lowered expense guidance. However, the company still reports a net loss, and the cash position, while bolstered by recent financing, remains a key area of focus, with a 'going concern' risk noted in forward-looking statements.

Positives

• Total revenue increased by 13.4% to $44.0 million in Q3 2025 compared to Q3 2024.
• U.S. XPOVIO net product revenue grew 8.5% to $32.0 million in Q3 2025, with consistent demand.
• Royalty revenue from international partners increased significantly to $1.5 million in Q3 2025.
• Loss from operations improved by approximately 42%, decreasing to $15.2 million in Q3 2025 from $26.3 million in Q3 2024.
• R&D expenses decreased by $5.6 million to $30.5 million in Q3 2025 due to lower clinical trial costs and cost-reduction initiatives.
• SG&A expenses decreased to $26.6 million in Q3 2025, reflecting cost reduction initiatives.
• Enrollment for the pivotal Phase 3 SENTRY trial in myelofibrosis was completed, a significant clinical milestone.
• Preliminary blinded aggregate safety data from the SENTRY trial suggests potential improvements in adverse events.
• Full-year 2025 expense guidance (R&D and SG&A) was lowered, indicating improved cost control.

Negatives

• Net loss slightly increased to $33.1 million in Q3 2025 from $32.1 million in Q3 2024.
• Cash, cash equivalents, restricted cash, and investments decreased to $46.2 million as of September 30, 2025, from $109.1 million at December 31, 2024, before the recent financing.
• Other expense for Q3 2025 was $7.4 million, a significant change from other income of $3.8 million in Q3 2024, primarily due to non-cash fair value remeasurements related to refinancing.

Risks

• No guarantee of successful commercialization of XPOVIO.
• No guarantee that any drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development will continue.
• No guarantee that positive developments in the drug candidate portfolio will result in stock price appreciation.
• Risks related to the adoption of XPOVIO in the commercial marketplace, and the timing and costs involved in commercializing XPOVIO or any approved drug candidates.
• Ability to obtain and retain regulatory approval for XPOVIO or any drug candidates.
• Uncertainty regarding the results of clinical and preclinical trials, including subsequent analysis of existing data and new data from ongoing and future trials.
• The content and timing of decisions made by regulatory authorities, investigational review boards, and publication review bodies, including the need for additional clinical trials.
• Ability of Karyopharm or its third-party collaborators to fully perform their respective obligations under applicable agreements.
• Ability to enroll patients in clinical trials.
• Potential for unplanned cash requirements and expenditures.
• Substantial doubt exists regarding Karyopharm's ability to continue as a going concern.
• Development or regulatory approval of drug candidates by competitors for products or product candidates in which Karyopharm is currently commercializing or developing.
• The direct or indirect impact of the COVID-19 pandemic or any future pandemic on Karyopharm's business, results of operations, and financial condition.
• Ability to obtain, maintain, and enforce patent and other intellectual property protection for any of its products or product candidates.

Future Outlook

Karyopharm expects its existing liquidity, including revenue from XPOVIO sales and license agreements, to fund planned operations into the second quarter of 2026. The company anticipates top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026, top-line data from the Phase 3 XPORT-MM-031 trial in multiple myeloma in the first half of 2026, and top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026. The company aims to maintain its commercial foundation for XPOVIO in multiple myeloma and support global launches by partners.

Management Comments

• Richard Paulson, President and CEO: "This has been a very productive quarter as we have strengthened our financial foundation and made meaningful clinical progress with enrollment completion of our Phase 3 SENTRY trial in myelofibrosis, marking a pivotal milestone for Karyopharm."
• Richard Paulson, President and CEO: "With SENTRY enrollment complete, our teams remain focused on clinical trial execution, preparing for top-line data in March, potential regulatory filings, and commercial launch readiness, as we work to redefine the standard-of-care for frontline myelofibrosis patients, pending regulatory approvals."

Industry Context

Karyopharm operates in the highly competitive oncology pharmaceutical market, focusing on novel cancer therapies like XPOVIO (selinexor), a first-in-class oral exportin 1 (XPO1) inhibitor. The company is addressing significant unmet needs in rare blood cancers like myelofibrosis, where current treatments (JAK inhibitors like ruxolitinib) often lead to anemia and treatment discontinuation. In endometrial cancer, Karyopharm is targeting TP53 wild-type tumors, particularly in patients with mismatch repair-proficient (pMMR) status, where immune checkpoint inhibitors show less benefit, highlighting a need for targeted therapies.

Comparison to Industry Standards

• In myelofibrosis, the only approved class of therapies are JAK inhibitors, including ruxolitinib. Karyopharm's selinexor in combination with ruxolitinib in the SENTRY trial aims to improve upon the current standard of care, particularly addressing issues like anemia and transfusion dependence which are correlated with poor prognosis.
• For endometrial cancer, the filing notes that while immune checkpoint inhibitors have shown benefit, the magnitude is greater for patients with dMMR tumors versus pMMR tumors. Karyopharm's XPORT-EC-042 trial targets TP53 wild-type advanced or recurrent endometrial cancer, specifically including pMMR patients, indicating an effort to address a patient population with a high unmet need where existing therapies are less effective.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and commercial performance improves, but ongoing net losses and 'going concern' risk present challenges.
• Patients: Potential for new treatment options for myelofibrosis and endometrial cancer if selinexor trials are successful and gain regulatory approval.
• Employees: Continued focus on clinical trial execution and commercialization efforts, supported by cost-reduction initiatives.
• Partners (Menarini Group, Antengene, Neopharm, FORUS): Growth in royalty revenue from international sales of selinexor, indicating successful global expansion.

Next Steps

• Conduct a conference call on November 3, 2025, to discuss Q3 2025 financial results and business updates.
• Prepare for top-line data readout from the Phase 3 SENTRY trial in myelofibrosis in March 2026.
• Prepare for potential regulatory filings and commercial launch readiness for selinexor in myelofibrosis, pending regulatory approvals.
• Continue to enroll JAKi-nave myelofibrosis patients in the Phase 2 SENTRY-2 trial, with top-line data from the 60 mg cohort expected in 2026.
• Continue to enroll patients in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with top-line data expected in mid-2026.
• Maintain the commercial foundation for XPOVIO in the multiple myeloma marketplace to drive increased revenues.
• Continue to support global launches by international partners following regulatory and reimbursement approvals for selinexor.
• Continue to follow patients enrolled in the Phase 3 XPORT-MM-031 trial, with top-line data expected in the first half of 2026.

Key Dates

Recommendation

Karyopharm has demonstrated solid operational progress with increased revenue, improved operating loss, and successful completion of a pivotal Phase 3 trial enrollment. The reaffirmation of revenue guidance and reduction in expense guidance are positive indicators of management's execution and cost control. However, the company continues to operate at a net loss, and the 'going concern' disclosure, while standard for development-stage biotechs, highlights ongoing financial risks. The recent capital raise provides some liquidity, but long-term funding will depend on pipeline success and commercial growth. Given the balance of clinical milestones and improved efficiency against persistent losses and inherent biotech risks, a 'hold' recommendation is appropriate for investors awaiting further definitive clinical data and sustained profitability.

Keywords

Karyopharm Therapeutics, KPTI, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, oncology, cancer therapy, clinical trials, SENTRY trial, financial results, biotechnology, pharmaceuticals, JAK inhibitor